Bionano Genomics, Inc.

How big is Bionano Genomics, Inc.?

As of Jun 18, Bionano Genomics, Inc. has a market capitalization of 10.97 million and reported net sales of 28.46 million with a net profit of -83.69 million over the last four quarters.

Market Cap: As of Jun 18, Bionano Genomics, Inc. has a market capitalization of 10.97 million, classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Bionano Genomics reported net sales of 28.46 million and a net profit of -83.69 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 35.38 million and total assets of 76.67 million.

What does Bionano Genomics, Inc. do?

Bionano Genomics, Inc. is a life sciences company focused on genome analysis, with a market cap of approximately $10.97 million and reported net sales of $6 million but a net loss of $3 million for Q1 2025. The company has no dividend yield and negative return on equity.

Overview: <BR>Bionano Genomics, Inc. is a life sciences instrumentation company in the genome analysis space, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Net Sales: 6 Million (Quarterly Results - Mar 2025) <BR>Net Profit: -3 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 10.97 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.30 <BR>Return on Equity: -142.04% <BR>Price to Book: 0.23<BR><BR>Contact Details: <BR>Address: 9540 Towne Centre Dr Ste 100, SAN DIEGO CA: 92121-1989 <BR>Tel: 1 858 8887600 <BR>Website: https://bionanogenomics.com/

Should I buy, sell or hold Bionano Genomics, Inc.?

Who are in the management team of Bionano Genomics, Inc.?

As of March 2022, Bionano Genomics, Inc.'s management team includes Dr. David Barker (Independent Chairman), Dr. R. Erik Holmlin (President and CEO), and several directors, including Dr. Yvonne Linney, Ms. Hannah Mamuszka, Dr. Albert Luderer, Mr. Christopher Twomey, and Dr. Kristiina Vuori, reflecting a diverse leadership structure.

As of March 2022, the management team of Bionano Genomics, Inc. includes the following individuals:<BR><BR>- Dr. David Barker, who serves as the Independent Chairman of the Board.<BR>- Dr. R. Erik Holmlin, who is the President, Chief Executive Officer, and a Director.<BR>- Dr. Yvonne Linney, who is a Director.<BR>- Ms. Hannah Mamuszka, who is also a Director.<BR>- Dr. Albert Luderer, serving as an Independent Director.<BR>- Mr. Christopher Twomey, who is an Independent Director.<BR>- Dr. Kristiina Vuori, who is another Independent Director.<BR><BR>In summary, the management team is composed of a mix of independent directors and key executives, highlighting a diverse leadership structure.

Is Bionano Genomics, Inc. technically bullish or bearish?

As of September 12, 2025, Bionano Genomics, Inc. has shifted to a neutral technical stance with mixed signals, showing mild bullishness in MACD but bearish trends in Bollinger Bands and moving averages, while significantly underperforming the S&P 500 with a year-to-date return of -89.66%.

As of 12 September 2025, the technical trend for Bionano Genomics, Inc. has changed from mildly bullish to sideways. The current technical stance is neutral, with mixed signals across various indicators. The MACD shows a mildly bullish stance on both weekly and monthly time frames, while the RSI indicates a bullish monthly signal but no signal on the weekly. However, Bollinger Bands and moving averages are bearish on the weekly and daily time frames, and Dow Theory is bearish on the weekly. Additionally, the stock has significantly underperformed compared to the S&P 500, with a year-to-date return of -89.66% versus the S&P 500's 12.22%.